ELOXX PHARMACEUTICALS, INC. Effective Income Tax Rate Reconciliation, Tax Credit, Percent
ELOXX PHARMACEUTICALS, INC. (ELOX) reported Effective Income Tax Rate Reconciliation, Tax Credit, Percent of 6.60% for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-31.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits · last filed 2023-03-31
- ELOXX PHARMACEUTICALS, INC. effective income tax rate reconciliation, tax credit, percent for fiscal 2022 was 6.60%, a 88.57% increase from fiscal 2021.
- ELOXX PHARMACEUTICALS, INC. effective income tax rate reconciliation, tax credit, percent for fiscal 2021 was 3.50%, a 20.69% increase from fiscal 2020.
- ELOXX PHARMACEUTICALS, INC. effective income tax rate reconciliation, tax credit, percent for fiscal 2020 was 2.90%.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Percent 12 month |
|---|---|
| 2022-12-31 | 6.60% 10-K · filed 2023-03-31 |
| 2021-12-31 | 3.50% 10-K · filed 2023-03-31 |
| 2020-12-31 | 2.90% 10-K · filed 2022-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Tevogen Inc. (TVGN) | United States | $0.049B |